Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations

Eitemau Tebyg

• E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy
  gan: Claudiani, Simone, et al.
  Cyhoeddwyd: (2017)
• Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy
  gan: Neelakantan, Pratap, et al.
  Cyhoeddwyd: (2012)
• MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia
  gan: Claudiani, Simone, et al.
  Cyhoeddwyd: (2019)
• The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib
  gan: Khorashad, Jamshid Sorouri, et al.
  Cyhoeddwyd: (2009)
• Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission
  gan: Serpa, Mariana, et al.
  Cyhoeddwyd: (2010)